Compare ServiceNow Inc (NOW) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Novartis AG — how do they compare? ServiceNow Inc trades at $140.1 (market cap $144.48B), while Novartis AG trades at $143.49 (market cap $268.57B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays a 3.31% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Novartis AG for 82 Days on average.
| NOW | NVS | |
|---|---|---|
Market Cap | $144.48B | $268.57B |
Volume | 11,801,699 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $189.26 | $168.62 |
52-Week Low | $83.00 | $121.80 |
Typical Hold Time | 54 Days | 82 Days |
Enterprise Value | $148.27B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $137.87, down slightly by 0.07% on the day. The stock shows strong fundamental momentum with revenue growing from $7.2B in 2022 to $13.3B in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish with the price above key moving averages, while analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $146.04 consensus target. The company's AI business has surpassed $1 billion in annual contract value, driving investor optimism.
ServiceNow presents a compelling growth story with robust AI adoption and expanding enterprise workflow solutions. The primary investment opportunity lies in the company's leadership position in enterprise AI and strong subscription revenue growth. Key risks include premium valuation multiples (P/E of 87.34), increasing competition in cloud software, and potential margin pressure as AI investments scale. The stock offers upside to analyst targets but requires monitoring of execution against ambitious growth projections.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
